{
    "nctId": "NCT02506790",
    "briefTitle": "Neoadjuvant Toremifene With Melatonin or Metformin in Locally Advanced Breast Cancer",
    "officialTitle": "Phase II Multicenter Randomized Study to Compare Neoadjuvant Toremifene With Melatonin or Metformin Versus Toremifene in the Therapy of Locally Advanced Breast",
    "overallStatus": "UNKNOWN",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 96,
    "primaryOutcomeMeasure": "Response rate",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Age \\> 18.\n* Obtained Inform Concent.\n* Morphologically confirmed breast cancer stage IIB, IIIA, IIIB, IIIC ER positive.\n* Eastern Collaborative Oncology Group Performance Status Scale 0-2.\n* Expected survival \\> 6 month.\n* Adequate liver and bone marrow function.\n\nExclusion Criteria:\n\n* Systemic treatment for breast cancer.\n* Stage IV disease.\n* Evidence of liver and bone marrow clinically meaningful disfunction.\n* Severe uncontrolled concomitant conditions and diseases.\n* Pregnancy or lactation.\n* Second malignancy.\n* Diabetes mellitus requiring drug therapy.\n* Any condition preventing study participation by investigators opinion.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}